Evolus (NASDAQ:EOLS) Trading Down 9.6% – What’s Next?

Evolus, Inc. (NASDAQ:EOLS) traded down 9.6% during trading on Monday . The stock traded as low as $12.56 and last traded at $12.28. 206,913 shares were traded during trading, a decline of 65% from the average session volume of 592,049 shares. The stock had previously closed at $13.58.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Stock Performance

The firm has a market cap of $808.19 million, a PE ratio of -13.97 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a 50 day simple moving average of $12.98 and a 200-day simple moving average of $14.03.

Institutional Trading of Evolus

Institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new stake in shares of Evolus during the fourth quarter valued at approximately $49,000. IFP Advisors Inc raised its holdings in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Evolus during the third quarter valued at approximately $132,000. KLP Kapitalforvaltning AS bought a new position in shares of Evolus during the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC bought a new position in Evolus in the fourth quarter worth $115,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.